Travere Therapeutics Balance Sheet
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics financial position
At the end of fiscal 2025, Travere Therapeutics reported total assets of $605.2 million, up 1.9% from a year earlier against total liabilities of $490.4 million. Shareholders' equity stood at $114.8 million, or 19.0% of assets. The company held $93.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.74, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 93.03M | 58.53M | 58.18M | 61.69M | 165.75M | 84.77M | 62.44M | 102.87M | 99.39M | 41.00M |
| Short-Term Investments | 145.38M | — | 248.64M | 285.53M | 262.19M | 271.80M | 209.49M | 208.47M | 123.27M | 214.87M |
| Receivables | 80.13M | 27.12M | 21.18M | 16.65M | 15.91M | 15.93M | 18.05M | 12.66M | 13.87M | 18.51M |
| Inventory | 36.16M | 41.86M | 9.41M | 4.52M | 7.31M | 7.61M | 6.08M | 5.62M | 5.35M | 2.83M |
| Total Current Assets | 437.56M | 416.70M | 616.77M | 486.44M | 582.83M | 410.41M | 429.06M | 495.68M | 325.81M | 332.35M |
| Property, Plant & Equipment | 4.02M | 5.34M | 7.48M | 9.05M | 11.11M | 9.42M | 2.89M | 3.15M | 3.23M | 2.59M |
| Goodwill | — | 800.00K | 800.00K | 800.00K | 900.00K | 900.00K | 936.00K | 936.00K | 936.00K | 936.00K |
| Intangible Assets | 113.87M | 103.97M | 104.44M | 97.07M | 148.44M | 154.13M | 157.20M | 186.69M | 184.82M | 182.04M |
| Long-Term Investments | 84.38M | — | 260.04M | 103.03M | 124.94M | 5.02M | 126.59M | 160.19M | 77.96M | — |
| Total Assets | 605.19M | 594.13M | 788.91M | 672.59M | 776.63M | 607.44M | 604.80M | 709.16M | 520.35M | 525.28M |
| Accounts Payable | 24.80M | 23.53M | 41.67M | 17.29M | 15.14M | 12.13M | 26.61M | 6.95M | 18.94M | 7.52M |
| Total Current Liabilities | 159.90M | 200.75M | 177.91M | 142.16M | 124.09M | 92.66M | 95.45M | 104.62M | 85.67M | 83.26M |
| Total Liabilities | 490.36M | 535.05M | 588.10M | 629.73M | 474.52M | 396.23M | 383.60M | 390.91M | 227.21M | 217.51M |
| Shareholders' Equity | 114.83M | 59.08M | 200.81M | 42.85M | 302.11M | 211.21M | 221.20M | 318.25M | 293.13M | 307.77M |
| Retained Earnings | -1.47B | -1.45B | -1.13B | -1.01B | -765.97M | -585.88M | -416.44M | -270.02M | -177.66M | -113.06M |
| Net Cash (Debt) | 238.42M | 58.53M | 306.81M | 347.21M | 427.94M | 356.57M | 271.93M | 311.35M | 222.67M | 255.87M |
| Shares Outstanding | 90.92M | 87.45M | 75.37M | 64.29M | 62.49M | 52.25M | 43.09M | 41.39M | 39.37M | 37.91M |
This table shows 10 annual periods of Travere Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TVTX's reporting calendar. What is a balance sheet?